Separate terms with OR to return results that match either term.
 
Clear All
10,000 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status (Descending)
71329-0104-01 71329-0104 Prednisone PREDNISONE 20.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Dec. 4, 2018 In Use
71329-0104-02 71329-0104 Prednisone PREDNISONE 20.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Dec. 4, 2018 In Use
71329-0105-01 71329-0105 Prednisone PREDNISONE 50.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Dec. 4, 2018 In Use
71329-0106-01 71329-0106 Prednisone PREDNISONE 1.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Jan. 4, 2019 In Use
71329-0106-02 71329-0106 Prednisone PREDNISONE 1.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Jan. 4, 2019 In Use
71329-0107-01 71329-0107 Prednisone PREDNISONE 2.5 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Dec. 11, 2018 In Use
71329-0108-01 71329-0108 Prednisone PREDNISONE 5.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Dec. 11, 2018 In Use
71329-0108-02 71329-0108 Prednisone PREDNISONE 5.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Dec. 11, 2018 In Use
00143-9098-01 00143-9098 Bortezomib Bortezomib 3.5 mg/1 Chemotherapy Proteasome Inhibitor 26S Intravenous, Subcutaneous July 27, 2022 In Use
00143-9135-01 00143-9135 Mitomycin Mitomycin 20.0 mg/1 Chemotherapy Antitumor Antibiotic Alkylating Agent/ Mitomycin Intravenous Oct. 1, 2022 In Use
00310-3512-60 00310-3512 Acalabrutinib CALQUENCE 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BTK Oral Aug. 4, 2022 In Use
00310-3512-95 00310-3512 Acalabrutinib CALQUENCE 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BTK Oral Aug. 4, 2022 In Use
00338-0720-01 00338-0720 PEMETREXED PEMETREXED 100.0 mg/10mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous Aug. 18, 2022 In Use
00409-1700-01 00409-1700 Bortezomib Bortezomib 3.5 mg/1 Chemotherapy Proteasome Inhibitor 26S Intravenous, Subcutaneous July 27, 2022 In Use
16729-0522-05 16729-0522 Pemetrexed disodium Pemetrexed 25.0 mg/mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous Sept. 8, 2022 In Use
16729-0522-28 16729-0522 Pemetrexed disodium Pemetrexed 25.0 mg/mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous Sept. 8, 2022 In Use
16729-0522-35 16729-0522 Pemetrexed disodium Pemetrexed 25.0 mg/mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous Sept. 8, 2022 In Use
16729-0522-64 16729-0522 Pemetrexed disodium Pemetrexed 25.0 mg/mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous Sept. 8, 2022 In Use
10135-0702-01 10135-0702 Hydroxyurea Hydroxyurea 500.0 mg/1 Chemotherapy Miscellaneous Agent Antimetabolite/Organooxygen Oral Jan. 28, 2022 In Use
00781-3258-70 00781-3258 Bortezomib Bortezomib 3.5 mg/1 Chemotherapy Proteasome Inhibitor 26S Intravenous May 31, 2022 In Use
00338-0722-01 00338-0722 PEMETREXED PEMETREXED 500.0 mg/50mL Chemotherapy Antimetabolite Folic Acid Analog INTRAVENTRICULAR Aug. 18, 2022 In Use
00143-9136-01 00143-9136 Mitomycin Mitomycin 40.0 mg/1 Chemotherapy Antitumor Antibiotic Alkylating Agent/ Mitomycin Intravenous Oct. 1, 2022 In Use
43598-0516-01 43598-0516 Lenalidomide Lenalidomide 2.5 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Sept. 6, 2022 In Use
43598-0516-63 43598-0516 Lenalidomide Lenalidomide 2.5 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Sept. 6, 2022 In Use
43598-0515-01 43598-0515 Lenalidomide Lenalidomide 25.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Sept. 6, 2022 In Use

Found 10,000 results in 7 milliseconds — Export these results